Evidence map›Paper›PMID 39936909›Full record

ArticleJournal of cellular and molecular medicine2025

Renal Lipid Alterations From Diabetes to Early-Stage Diabetic Kidney Disease and Mitophagy: Focus on Cardiolipin.

Zhijie Li, Hongmiao Wang, Nan Liu, Xiayuchen Lan, Ailing Xie, Ge Yuan, Bowen Li, Jiaxin Geng, Xiaodan Liu

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. New Insights into the Role of Mitochondrial Dysfunction in Diabetic Kidney Disease in the Omics Era.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhijie LiDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Hongmiao WangDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Nan LiuDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiayuchen LanDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ailing XieDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ge YuanDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Bowen LiLipidALL Technologies Company Limited, Changzhou, Jiangsu, China.
Jiaxin GengLipidALL Technologies Company Limited, Changzhou, Jiangsu, China.
Xiaodan LiuDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID 0000-0001-9112-1032

Funding

"PRO•Run" Fund of the Nephrology Group of CEBM KYJ202206-0003-2The Educational Department of Liaoning Province LJKZ0738
6 · The paper itself

Abstract

Lipotoxicity plays a crucial role in the progression of diabetic kidney disease (DKD), yet the dynamic changes in renal lipid composition from diabetes to early-stage DKD remain unclear. Free fatty acids, lactosylceramides and cardiolipin (CL) were identified as the most significantly altered lipids by quantitatively comparing targeted lipids in the renal cortex of the classic spontaneous diabetic db/db mice using high-coverage targeted lipidomics. Further investigation into the causes and effects of decreased CL, which is a unique mitochondrial phospholipid, was conducted in mitochondria-rich renal proximal tubular cells by using western blotting, real-time PCR, immunohistochemistry and transmission electron microscopy. Reduced expression of cardiolipin synthase, a key enzyme in the CL synthesis pathway, and inhibition of CL-related mitophagy were confirmed under high glucose conditions. In addition, the protective effect of CL-targeted Szeto-Schiller 31 in preserving mitophagy was demonstrated in both in vivo and in vitro studies. These findings provide new insights into the pathogenesis of early-stage DKD from a lipid perspective and offer a theoretical basis for discovering new treatments.

Indexed as

CardiolipinsDiabetic NephropathiesKidneyLipid MetabolismMitophagyAnimalsDiabetes Mellitus, ExperimentalLipidomicsMaleMiceMice, Inbred C57BLMitochondriaCardiolipinscardiolipincardiolipin synthasediabetic kidney diseasefree fatty acidlipidomicsmitophagyproximal tubulesphingolipidSzeto‐Schiller 31

Identifiers

PMID39936909
PMCPMC11816159

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.